Business Context and Reporting Period
Company: Autonomix Medical, Inc. (AMIX)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2026
Business Overview: A development-stage medical device company focused on a catheter-based system for sensing and treating disorders of the nervous system, initially targeting pain associated with pancreatic cancer. The company has no product revenue and is in the pre-commercial phase.
Key Financial Metrics
| Metric | Q2 2026 | Q2 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(2.73) million | $(3.34) million |
| Operating Expenses | $(2.77) million | $(3.42) million |
| Cash and Cash Equivalents (End of Period) | $3.46 million | $8.59 million |
| Working Capital | $3.16 million | $7.03 million |
| Accumulated Deficit | $(69.82) million | $(53.72) million |
| Net Cash Used in Operating Activities | $(3.54) million | $(2.60) million |
Material Changes vs. Prior Period
- Expense Reduction: Total operating expenses decreased by 19% ($0.65 million) compared to the prior year quarter. General and Administrative (G&A) expenses dropped 31% primarily due to a $0.3 million reduction in stock-based compensation following stock option cancellations in late 2025.
- Cash Burn: Net cash used in operating activities increased by $0.94 million year-over-year, despite lower net loss, due to changes in operating assets and liabilities (specifically decreases in accounts payable and accrued expenses).
- Capital Structure: The company executed a 1-for-21 reverse stock split effective June 24, 2026. All share and per-share data in the filing have been retroactively adjusted.
- Listing Status: The company regained compliance with the Nasdaq Bid Price Rule in July 2026 after previously receiving a deficiency notice in January 2026.
Outlook, Risks, and Management Commentary
- Liquidity and Going Concern: Management states there is substantial doubt about the company's ability to continue as a going concern. Current cash resources are estimated to fund operations only into the first calendar quarter of 2027. The company estimates it requires an additional $25 million to $30 million to reach commercialization.
- Recent Financing (Subsequent Event): On July 13, 2026, the company entered into a warrant inducement agreement, receiving approximately $2.6 million in gross proceeds from the exercise of Series C warrants. New Series D-1 and D-2 warrants were issued in exchange.
- Clinical Development: Enrollment in an early clinical proof-of-concept study was paused to evaluate variability in outcomes related to vascular access and anatomical targeting. The company is refining its clinical approach.
- Internal Controls: The company disclosed material weaknesses in internal control over financial reporting, citing a lack of segregation of duties and limited staffing. Disclosure controls and procedures were deemed ineffective as of June 30, 2026.
- Regulatory Risk: A new Nasdaq rule requiring a minimum Market Value of Listed Securities (MVLS) of $5 million poses a delisting risk if not met, though the rule was stayed pending SEC review as of late July 2026.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $2.6 million raised in July 2026 to extend the operating runway beyond Q1 2027.
- Capital Requirements: Assess the feasibility of raising the estimated $25–$30 million needed for commercialization given current market conditions and the company's stock price volatility.
- Clinical Progress: Monitor updates on the paused clinical trial and the timeline for resuming enrollment.
- Internal Controls: Review the remediation plan for material weaknesses in financial reporting and segregation of duties.
- Nasdaq Compliance: Track the status of the MVLS rule and the company's market capitalization to ensure continued listing.